CPHI 2024
September 2024.
Fisiopharma will join CpHI Milano 2024.
After its takeover by the Polish company Bioton in 2008, it was then acquired by the Yifan Pharmaceuticals Ltd group in 2018. This international biopharmaceutical company has operations and headquarters in Europe, Asia and the USA, 20 production plants and more than 5,000 employees worldwide.
Fisiopharma currently employs 112 people covering the production plant in Palomonte (SA) and the commercial offices in the centre of Milan.
Fisiopharma has a long lasting cooperation with sister company Pharmatex Italia, which is also part of the Yifan Pharmaceuticals Ltd group. Pharmatex Italia is dedicated to the distribution of hospital products in Italy and abroad.
Our three main product categories:
Sterile solutions in vials and ampoules manufactured through septic filling and terminal sterilisation.
Sterile suspensions and nanoemulsions in vials and ampoules manufactured through aseptic filling.
Filling of sterile powders in vials through aseptic filling.
Fisiopharma holds MA registrations in Italy, Europe and non-European countries for several products, including antibiotics, local and systemic anaesthetics and systemic anti-inflammatories. These are marketed directly in Italy through hospitals and in Europe or worldwide through distribution and licensing agreements.
Development and production of injectable drugs for international customers. Management of the entire production process, including analysis of raw materials, excipients and finished products; and production, packaging and serialisation where required. Extensive experience in project management, technology transfer and development and validation of production and analytical processes.
Fisiopharma develops and licenses generic drugs and acts as development and production partner with international customers.
Thanks to the technical skills and specialisation of its staff, to a constant focus on training and continuous improvement, and to collaboration with universities, laboratories and cutting-edge companies, Fisiopharma constantly works in developing formulations, processes and new production technologies in the injectable drugs field.
At Fisiopharma, our personnel are experts specialised in the field of injectable drug production: 37% of staff are university graduates, the average tenure is 13 years and the average age of employees is 45 years.
Through a well-established training plan, staff are constantly updated and trained on the main quality, regulatory and production aspects. To this end, Fisiopharma also works with internationally renowned and respected consulting companies.
Fisiopharma works with Italian universities and laboratories, as well as with experienced companies in regulation, quality and production, to maintain high production and quality standards and meet the needs of its customers.
The most relevant news about our services and products.
September 2024.
Fisiopharma will join CpHI Milano 2024.
Always a great experience to join the DCAT Week in NYC.
This year too we will be present at the most important pharmaceutical event of the year with exhibitors and participants from all over the world.